Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| European Society of Anaesthesiology | OTHER |
Not provided
Not provided
Not provided
Not provided
The potential benefits of preserved early spontaneous breathing activity during mechanical ventilation are an increased aeration of dependent lung regions, less need for sedation, improved cardiac filling, and better matching of pulmonary ventilation and perfusion and thus oxygenation. Two small randomized controlled trials (RCTs) in patients with acute respiratory distress syndrome (ARDS) reported less time on mechanical ventilation and in the intensive care unit (ICU) with preserved early spontaneous breathing activity during Airway Pressure Release Ventilation (APRV).
Debate exists over the net effects of preserved early spontaneous breathing activity with regard to ventilator-associated lung injury (VALI). In fact, by taking advantage of the potential improvement in oxygenation and recruitment at lower inflation pressures associated with APRV, physicians could possibly reduce potentially harmful levels of inspired oxygen, tidal volume, and positive end-expiratory pressure (PEEP). However, spontaneous breathing during mechanical ventilation has the potential to generate less positive pleural pressures that may add to the alveolar stretch applied from the ventilator and contribute to the risk of VALI. This has led to an ongoing controversy whether an initial period of controlled mechanical ventilation with deep sedation and neuromuscular blockade or preserved early spontaneous breathing activity during mechanical ventilation is advantageous with respect to outcomes in ARDS patients.
A RCT investigating the effects of early spontaneous breathing activity on mortality in moderate to severe ARDS has been highly recommended in the research agenda for intensive care medicine.
The objective of this study is to evaluate the efficacy and safety of preserved spontaneous breathing activity during APRV in the early phase of moderate to severe ARDS.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Spontaneous Breathing Group | Experimental | Spontaneous breathing activity will be allowed during APRV within one hour after randomization throughout the first 48 hours. After 48 hours, standard routine care should be provided in both groups, although we suggest moderate sedation while spontaneous breathing is maintained with APRV, pressure support ventilation (PSV), or other assisting ventilator modes. Weaning off mechanical ventilation will be performed after 48 hours according to a protocol using spontaneous breathing trials. |
|
| Controlled Mechanical Ventilation Group | Experimental | Pressure controlled mechanical ventilation will be applied throughout the first 48 hours. After 48 hours, standard routine care should be provided in both groups, although we suggest moderate sedation while spontaneous breathing is maintained with APRV, pressure support ventilation (PSV), or other assisting ventilator modes. Weaning off mechanical ventilation will be performed after 48 hours according to a protocol using spontaneous breathing trials. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| spontaneous breathing activity during APRV | Procedure | Allowing spontaneous breathing activity with APRV throughout the first 48 hours. |
|
| Measure | Description | Time Frame |
|---|---|---|
| All-cause mortality at study day 28 (D28) | All-cause mortality at D28 will be defined as number of patients deceased at D28 divided by number of all patients. In case of missing survival status in more than 1% of the patients, additional analyses will be carried out using multiple imputation or estimating-equation methods. The date of death will be recorded for all patients who die. Up to D28, the patient's location at the time of death (ICU or hospital) will also be recorded. | All-cause mortality at D28 will be defined as number of patients who deceased at day 28. |
| Number of Ventilator Free Days (VFD) until day 28 (D28) | Number of VFDs until D28 are defined as number of days alive and completely off the ventilator until day 28. A patient will be reported as ventilator free after two consecutive calendar days of unassisted spontaneous breathing (UAB). UAB is defined as:
Patients still on positive pressure ventilation/receiving assisted breathing who are transferred to another hospital or healthcare facility prior to D28 will be followed up to assess the VFD outcome at D28. | Number of Ventilator Free Days will be measured until day 28. |
| Measure | Description | Time Frame |
|---|---|---|
| All-Cause Mortality Rate at study day 90 (D90) | All-cause mortality at D90 is defined as number of patients deceased at D90 divided by number of all patients. Patients with missing survival status will be counted as non-survivor. | All-cause mortality at D90 will be defined as number of patients who deceased at day 90. |
| Measure | Description | Time Frame |
|---|---|---|
| Level of Sedation until study day 7 (D7) | Level of Sedation will be determined using the Ramsay scale [minimum value: 1 (anxious, agitated, restless) to 6 (no response to light glabellar tap or loud auditory stimulus)], the Richmond Agitation- Sedation Scale [minimum value: -5 (unarousable) to +4 (combative)], or the Riker Sedation-Agitation Scale [minimum value: 1 (unarousable) to 7 (dangerous agitation)]. Sedation/analgesia according to local standard will be titrated to achieve either a deep or a moderate sedation level. Deep sedation is defined as a Ramsay score of 5 to 6, which corresponds to a Richmond Agitation-Sedation Scale (RASS) of -4 to -5 or a Riker Sedation-Agitation Scale of 1 to 2. Moderate sedation is defined as a Ramsay score of 2 to 3, which corresponds to a RASS of 0 to -1 or a Riker Sedation-Agitation Scale of 3 to 4. |
Inclusion Criteria:
Moderate to severe ARDS for ≤ 48 hours according to the Berlin definition will be defined by acute onset of:
Requirement for positive pressure ventilation via an endotracheal tube/ tracheotomy
Presence of informed consent according to local regulations
Age ≥ 18 years
Expected duration of mechanical ventilation > 48 hours at randomization
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Christian Putensen, M.D., PhD. | Contact | +49 228 287 | 14119 | Christian.Putensen@ukbonn.de |
| Stefan Muenster, M.D. | Contact | +49 228 287 | 14119 | Stefan.Muenster@ukbonn.de |
| Name | Affiliation | Role |
|---|---|---|
| Christian Putensen, M.D., PhD. | University Hospital, Bonn | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University Hospital Bonn, Department of Anesthesiology and Critical Care Medicine | Recruiting | Bonn | 53127 | Germany |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D012128 | Respiratory Distress Syndrome |
| D055397 | Ventilator-Induced Lung Injury |
| ID | Term |
|---|---|
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D012120 | Respiration Disorders |
| D055370 | Lung Injury |
Not provided
Not provided
Not provided
Not provided
Not provided
Double
| No spontaneous breathing activity | Procedure | No spontaneous breathing activity will be allowed with pressure controlled ventilation throughout the first 48 hours. |
|
| Number of Vasoactive Drug Free Days until study day 28 (D28) |
Number vasoactive drug free days are defined as number of days alive and completely off the vasoactive drugs until D28. Any vasoactive support given to the patient will be recorded in the e-CRF. Vasoactive support includes: catecholamine and non-catecholamine vasopressors, inotropes and vasodilating agents. |
| Number of Vasoactive Drug Free Days will be measured until D28. |
| Number of Renal Support Free Days until study day 28 (D28) | Number of Renal Support Free Days are defined as number of days alive and completely off the renal support until day 28. Any renal support given to the patient will be recorded on a specific page in the e-CRF. | Number of Renal Support Free Days will be measured until study day 28. |
| Sequential Organ Failure Assessment (SOFA) | Organ failure status will be assessed using the mean SOFA score, which assesses six organ systems: respiration, coagulation, liver, cardiovascular, central nervous system and renal function. A patient will be defined as being free of organ failure when the SOFA score is zero. | The score will be assessed pre-randomization on study day 1 (D1) and daily up to study day 7 (D7) and while the patient is in the ICU until D28. |
| For each study day, the distribution of Ramsay scale, Richmond Agitation-Sedation Scale, or Riker Sedation-Agitation Scale and the number of patients deviating from the target will be described until D7. |
| Level of Analgesia until study day 7 (D7) | Level of analgesia will be determined using the Behavioural Pain Scale for pain assessment in intubated patients. The Behavioral Pain Scale quantifies pain using body language and patient-ventilator interactions for intubated patients. Minimum value: 3 (calm, no pain), maximum value: 12 (maximum pain, restless). | The distribution of Behavioural Pain Scale will be described for each study day until D7. |
| Occurrence of barotrauma w/o Chest Tube until ICU discharge or study day 28 (D28) | Barotrauma will be defined as newly developed pneumothorax, pneumomediastinum, subcutaneous emphysema, or pneumatocele larger than 2 cm in diameter with and without a chest tube and will be reported as adverse event (AE). | The number of patients with barotrauma will be counted until ICU discharge or D28 whatever comes first. |
| Occurrence of pneumonia until ICU discharge or study day (D28) | Any newly acquired pneumonia either microbiologically confirmed or radiologically and clinically suspected by the American Thoracic Society definition requiring antimicrobial treatment. | Will be counted until ICU discharge or D28 whatever comes first. |
| Weaning Failure until study day 28 (D28) | Weaning failure will be reported as failure to pass SBTs until D28. The proportion of patients with weaning failure will be analyzed. | Will be measured until D28. |
| Use of Prone Positioning until study day 28 (D28) | Prone positioning will be recorded until study day 28 (D28). The proportion of patients with prone positioning will be analyzed. | Will be counted until D28. |
| Use of Extra-corporeal Membrane Oxygenation (ECMO) as a rescue therapy until study day 28 (D28) | In refractory hypoxemia (PaO2/FIO2 < 60 mmHg) and in patients who do not respond with a substantial increase in arterial oxygenation in the transition from lower to higher PEEP a rescue therapy is allowed. The proportion of patients with Extra-corporeal Membrane Oxygenation (ECMO) will be analyzed. | Use of Extra-corporeal Membrane Oxygenation (ECMO) will be counted until study day 28 (D28). |
| Use of an inhaled vasodilator (e.g. inhaled nitric oxide) as a rescue therapy until study day 28 (D28) | In refractory hypoxemia (PaO2/FIO2 < 60 mmHg) and in patients who do not respond with a substantial increase in arterial oxygenation in the transition from lower to higher PEEP a rescue therapy is allowed. The proportion of patients with the use of an inhaled vasodilator will be analyzed. | Use of an inhaled vasodilator will be counted until study day 28 (D28). |
| Use of an neuromuscular blocking agent (NMBA) (if not in the Control Group) as a rescue therapy until study day 28 (D28) | In refractory hypoxemia (PaO2/FIO2 < 60 mmHg) and in patients who do not respond with a substantial increase in arterial oxygenation in the transition from lower to higher PEEP a rescue therapy is allowed. The proportion of patients with the use of an neuromuscular blocking agent (NMBA) (if not in the Control Group) will be analyzed. | Use of an neuromuscular blocking agent (NMBA) (if not in the Control Group) will be counted until study day 28 (D28). |
| Use of high-frequency oscillation as a rescue therapy until study day 28 (D28) | In refractory hypoxemia (PaO2/FIO2 < 60 mmHg) and in patients who do not respond with a substantial increase in arterial oxygenation in the transition from lower to higher PEEP a rescue therapy is allowed. The proportion of patients with the use of high-frequency oscillation will be analyzed. | Use of high-frequency oscillation will be counted until study day 28 (D28). |